Design strategies for protein kinase inhibitors

Medicine & Life Sciences

• Protein Kinase Inhibitors 71%
• Allosteric Site 47%
• Growth Factor Receptors 39%
• Protein-Serine-Threonine Kinases 37%
• Heat-Shock Proteins 35%
• Drug Discovery 34%
• Protein Kinases 31%
• Protein-Tyrosine Kinases 30%
• Phosphotransferases 26%
• Binding Sites 25%
• Clinical Studies 23%
• Inflammation 19%
• Mutation 18%
• Pharmaceutical Preparations 13%
• Neoplasms 10%

Chemical Compounds

• Protein Kinase Inhibitor 100%
• Growth Factor 39%
• Threonine 37%
• Drug 35%
• Tyrosine 30%
• Disorder 28%
• Mutation 28%
• Protein 27%
• Heat 24%
• Binding Site 23%